- BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
- BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
- BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
- BioLineRx to Report First Quarter 2024 Results on May 28, 2024
- BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
- BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
- BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
- BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
- BioLineRx Announces $6 Million Registered Direct Offering
- BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
More ▼
Key statistics
On Thursday, Bioline Rx Ltd (BLRX:TLV) closed at 17.30, 14.57% above the 52 week low of 15.10 set on May 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.90 |
---|---|
High | 17.60 |
Low | 16.50 |
Bid | 16.80 |
Offer | 17.10 |
Previous close | 17.20 |
Average volume | 525.45k |
---|---|
Shares outstanding | 1.20bn |
Free float | 1.20bn |
P/E (TTM) | -- |
Market cap | 207.85m ILS |
EPS (TTM) | -0.1891 ILS |
Data delayed at least 20 minutes, as of Jun 13 2024 15:24 BST.
More ▼